

## Acquisition of own shares

### **BRUSSELS, Belgium, 14 March 2013 – 19:30 (CET) – regulated information –**

In application of art. 207 of the Royal Decree executing the Company Code, UCB SA/NV announces that, it has, with trade date 12 March 2013 as an execution of a discretionary mandate, sold 120,000 UCB share options, previously purchased in June 2011, to a bank counterparty with strikes and maturity dates as follows :

- 30,000 options maturing 19 May 2017 with strike € 28
- 30,000 options maturing 19 May 2017 with strike € 30
- 30,000 options maturing 19 May 2017 with strike € 32
- 30,000 options maturing 19 May 2017 with strike € 34

In a related transaction, UCB SA has purchased from the same counterparty 120,000 UCB shares at a price of € 48.99 per share. This share price is within the high (€ 49.315) and low (€ 48.10) of the trading range of 12 March 2013.

In a separate transaction UCB has also acquired 1,614 UCB shares on the Brussels stock exchange on the date and at the price indicated hereunder:

Date	Price EUR	Amount
12/03/2013	48.66	1,614

These shares were distributed to the employees in the context of share grants in the framework of existing Company's stock award plans and stock performance plans of which the detail is given in UCB annual report.

After these transactions UCB SA is the owner of 710.760 UCB shares and 2,500,000 assimilates securities which together represent 1.75% of the total (183,417,352) shares issued by the company.

**UCB S.A. - Allée de la Recherche, 60 - 1070 Brussels - RPM 0403.053.608**

#### **For further information**

Antje Witte, Investor Relations, UCB  
T +32.2.559.9414, [antje.witte@ucb.com](mailto:antje.witte@ucb.com)

#### **About UCB**

UCB, Brussels, Belgium ([www.ucb.com](http://www.ucb.com)) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 9000 people in approximately 40 countries, the company generated revenue of EUR 3.4 billion in 2012. UCB is listed on Euronext Brussels (symbol: UCB).

### **UCB Forward-looking statements**

*This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees. UCB is providing this information as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.*

*There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed.*

*Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.*